Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03595800 | Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen(HaploMUD-RIC) | completed | Phase 3 | 9 | Institut Paoli-CalmettesOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT02563002 | Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) | completed | Phase 3 | 307 | Merck Sharp & Dohme LLC |
| 0 |
| Oct 3, 2024 |
| clinicaltrials |
| NCT03635489 | A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 3 | 100 | Hoffmann-La RocheINDUSTRY | 1 | Oct 3, 2024 | clinicaltrials |
| NCT05600322 | Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer | completed | Phase 3 | 158 | PhotocureINDUSTRY | 1 | Oct 3, 2024 | clinicaltrials |
| NCT03875092 | A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study | completed | Phase 3 | 125 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04852679 | Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs(PALACE) | completed | Phase 3 | 43 | IpsenINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT02028507 | Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors(PEARL) | completed | Phase 3 | 693 | Spanish Breast Cancer Research GroupOTHER | 4 | Sep 25, 2024 | clinicaltrials |
| NCT04737187 | Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients(SUNLIGHT) | completed | Phase 3 | 492 | Taiho Oncology, Inc.INDUSTRY | 14 | Sep 24, 2024 | clinicaltrials |
| NCT00004112 | Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma | completed | Phase 3 | — | University of NebraskaOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT00365105 | Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer | completed | Phase 3 | 261 | Radiation Therapy Oncology GroupNETWORK | 1 | Sep 20, 2024 | clinicaltrials |
| NCT02578680 | Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) | completed | Phase 3 | 616 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 20, 2024 | clinicaltrials |
| NCT02845479 | The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I(POISE) | completed | Phase 3 | 22 | The Canadian College of Naturopathic MedicineOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT00072462 | Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ(IBIS-II DCIS) | completed | Phase 3 | 2,980 | Queen Mary University of LondonOTHER | 14 | Sep 19, 2024 | clinicaltrials |
| NCT00400179 | A Safety and Efficacy Study in Patients With Gastric Cancer | completed | Phase 3 | 1,053 | Taiho Oncology, Inc.INDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT01607957 | Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies(RECOURSE) | completed | Phase 3 | 800 | Taiho Oncology, Inc.INDUSTRY | 13 | Sep 19, 2024 | clinicaltrials |
| NCT01724346 | Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 3 | 269 | Pharmacyclics LLC.INDUSTRY | 16 | Sep 19, 2024 | clinicaltrials |
| NCT02864394 | Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033) | completed | Phase 3 | 425 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 19, 2024 | clinicaltrials |
| NCT04776083 | Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients | completed | Phase 3 | 75 | Menoufia UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05136898 | Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) | completed | Phase 3 | 8 | UroGen Pharma Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06601205 | Finasteride and Flutamide in Pre-surgical Trial in Prostate Cancer.(2F) | completed | Phase 2 / Phase 3 | 125 | Ente Ospedaliero Ospedali GallieraOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03078855 | A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma(ILyAD) | completed | Phase 3 | 211 | Jonathan FriedbergOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT02500043 | Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer | completed | Phase 3 | 507 | Taiho Oncology, Inc.INDUSTRY | 18 | Sep 3, 2024 | clinicaltrials |
| NCT03598270 | Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer(ANITA) | completed | Phase 3 | 417 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 5 | Aug 30, 2024 | clinicaltrials |
| NCT04385368 | Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)(MERMAID-1) | completed | Phase 3 | 89 | AstraZenecaINDUSTRY | 33 | Aug 30, 2024 | clinicaltrials |
| NCT01272050 | Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery | completed | Phase 3 | 350 | Swiss Cancer InstituteOTHER | 3 | Aug 28, 2024 | clinicaltrials |
| NCT01404156 | Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma(POWERRANGER) | completed | Phase 2 / Phase 3 | 29 | Dr. Gordon BuduhanOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT01906216 | Sorafenib Chemoembolization Evaluation Controlled Trial(SELECT) | completed | Phase 3 | 199 | Air Force Military Medical University, ChinaOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT02920008 | Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia | completed | Phase 3 | 302 | Astex Pharmaceuticals, Inc.INDUSTRY | 15 | Aug 28, 2024 | clinicaltrials |
| NCT02348489 | SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction | completed | Phase 3 | 815 | Astex Pharmaceuticals, Inc.INDUSTRY | 24 | Aug 27, 2024 | clinicaltrials |
| NCT02907359 | Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs | completed | Phase 3 | 417 | Astex Pharmaceuticals, Inc.INDUSTRY | 14 | Aug 27, 2024 | clinicaltrials |
| NCT03306264 | Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML | completed | Phase 3 | 227 | Astex Pharmaceuticals, Inc.INDUSTRY | 10 | Aug 27, 2024 | clinicaltrials |
| NCT00220792 | Group Therapy for Primary Breast Cancer | completed | Phase 3 | 480 | Stanford UniversityOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT00991211 | Bendamustine Plus Rituximab Versus CHOP Plus Rituximab | completed | Phase 3 | 549 | University of GiessenOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT01456351 | Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab | completed | Phase 3 | 230 | University of GiessenOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT00297791 | COLOR II: Laparoscopic Versus Open Rectal Cancer Removal(COLORII) | completed | Phase 3 | 1,044 | Nova Scotia Health AuthorityOTHER | 9 | Aug 21, 2024 | clinicaltrials |
| NCT03110562 | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma(BOSTON) | completed | Phase 3 | 402 | Karyopharm Therapeutics IncINDUSTRY | 21 | Aug 21, 2024 | clinicaltrials |
| NCT03402841 | Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients(OPINION) | completed | Phase 3 | 279 | AstraZenecaINDUSTRY | 19 | Aug 21, 2024 | clinicaltrials |
| NCT02112656 | Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)(OPTIMA) | completed | Phase 3 | 554 | ImunonINDUSTRY | 14 | Aug 20, 2024 | clinicaltrials |
| NCT02989857 | Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)(ClarIDHy) | completed | Phase 3 | 187 | Institut de Recherches Internationales ServierOTHER | 6 | Aug 20, 2024 | clinicaltrials |
| NCT00469417 | Metvix Photodynamic Therapy (PDT) Versus Cryotherapy in Participants With Primary Superficial Basal Cell Carcinoma | completed | Phase 3 | 120 | Galderma R&DINDUSTRY | 7 | Aug 19, 2024 | clinicaltrials |
| NCT00725374 | A Study to Investigate the Effects of Tibolone (Livial®) on Breast Tissue in Postmenopausal Women With Breast Cancer (Study 32971)(P06469)(STEM) | completed | Phase 3 | 102 | Organon and CoINDUSTRY | 0 | Aug 15, 2024 | clinicaltrials |
| NCT02326311 | Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response | completed | Phase 3 | 229 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05290545 | Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT | completed | Phase 3 | 314 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05865548 | Addition of Aspirin to Standard of Care in Oral Cancer | completed | Phase 2 / Phase 3 | 60 | Banaras Hindu UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT03520946 | RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients(RAMTAS) | completed | Phase 3 | 430 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03275636 | Haploidentical Donor vs mMUD in Hematological Malignancies(HAMLET) | completed | Phase 2 / Phase 3 | 98 | DKMS gemeinnützige GmbHOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT04296890 | A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression(SORAYA) | completed | Phase 3 | 106 | ImmunoGen, Inc.INDUSTRY | 11 | Aug 7, 2024 | clinicaltrials |
| NCT02668653 | Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)(QuANTUM-First) | completed | Phase 3 | 539 | Daiichi SankyoINDUSTRY | 28 | Aug 6, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Oct 4, 2024source: clinicaltrials